Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) produce significant, clinically meaningful weight loss (7–21%) and improve cardiometabolic markers in adults and adolescents with obesity.
If you have obesity, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available, producing weight loss comparable to bariatric surgery. They work by mimicking hormones that regulate appetite and digestion. While they require weekly (or daily) injections and can cause temporary gastrointestinal side effects, they also improve blood pressure, blood sugar, and cholesterol. Because obesity is a chronic disease, these medications are intended for long-term use to maintain weight loss, not just short-term fixes.
Treatment with liraglutide 3.0 mg daily resulted in average weight reductions of 7–8%... Semaglutide 2.4 mg once weekly achieved losses of 14–17%... Tirzepatide... demonstrated unprecedented efficacy, with reductions of up to 20.9%... Across all agents, improvements were observed in glycemic control, blood pressure, and lipid metabolism.
Why this rating
Based on multiple large-scale RCTs (SCALE, STEP series, SURMOUNT-1) and systematic reviews.
Source
GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW
Natalia Strumnik et al. · International Journal of Innovative Technologies in Social Science · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →